London Business School (LBS) is proud to announce the launch of its LBS Corporate 100 alliance, an exclusive community of ...
Today, on 24 September 2025, Loihde Plc's Board of Directors has decided to issue a total of 6,842 new shares as part of the Group's Employee Share Savings Plan (ESSP).
Denodo, a leader in data management, announced the availability of a new study conducted by independent analyst firm Veqtor8. The study compared the ROI of using the Denodo Platform alongside data ...
SkiStar AB will publish the Year-End Report for the period 1 September 2024 – 31 August 2025 on Wednesday 1 October 2025 at 07.00 a.m. CEST. In connection with the report SkiStar will organize a ...
Lumina Datamatics, a strategic partner to global publishers and eCommerce retailers, is pleased to announce that it has been honored with the prestigious Indo–American Corporate Excellence (IACE) ...
The Board of Directors of F-Secure Corporation resolved, based on the authorization granted by the Annual General Meeting of Shareholders 1 April 2025, on a directed share issue without consideration ...
Through this collaboration, Kempower and FREEDM will conduct research in electric system reliability, energy management, and charging energy systems to expand market and industry knowledge. This ...
On 23 September 2025, the reverse share split of Summa Defence Plc shares, as previously announced, has been executed. The arrangement includes the reduction in the number of shares, a directed share ...
AGF Management Limited (AGF or the Company) (TSX: AGF.B) today announced financial results for the third quarter ended August 31, 2025. AGF reported total assets under management and fee-earning ...
Heathrow (LHR) is top ranked for a third consecutive year. Istanbul (IST) climbs six places from 2024 to second ranked Megahub in 2025. Asia dominates low-cost with Kuala Lumpur (KUL) top for low-cost ...
This agreement represents the first Ayla deployment and first time deploying CST in an NHS primary care setting, positioning Brain+ to expand adoption with individual practices and at scale through ...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...